Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 1, 2012, Pages 157-164

  Schuette, Wolfgang ^a   Krzakowski, MacIej J ^b   Massuti, Bartomeu ^c   Otterson, Gregory A ^d   Lizambri, Richard ^e   Wei, Helen ^e   Berger, Dietmar P ^e   Chen, Yuhchyau ^f  

^a Krankenhaus Martha Maria Halle Doelau   (Germany)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d OHIO STATE UNIVERSITY   (United States)

^e AMGEN INC   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Dysphagia; Lung; Non small cell

Indexed keywords

CARBOPLATIN; PACLITAXEL; PALIFERMIN; PLACEBO;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG SAFETY; DYSPHAGIA; ERYTHEMA; FEMALE; FLUSHING; HUMAN; HYPOXIA; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SHOCK; SIDE EFFECT; SUDDEN DEATH; TREATMENT RESPONSE;

EID: 84655162731     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822f6526     Document Type: Article

References (34)

1. Curran W, Scott C, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:621.
2. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699. (Pubitemid 29415225)
3. Pierre F, Maurice P, Gilles R. A randomized phase III trial of sequential chemoradiotherapy versus concurrent chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC) (GLOTGFPC NPC 95-01 study). Proc Am Soc Clin Oncol 2001;20:312A.
4. Auperin A, Rolland E, Curran WJ, et al. Concomitant readio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced nonsmall cell lung cancer (CSCLC): A meta analysis using individual patient data (IPD) from randomised clinical trials. J Thorac Oncol 2007;2:S310.
5. Belderbos J, Uitterhoeve L, van Zandwijk N, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007;43:114-121. (Pubitemid 46054477)
6. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon- Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo- Cancerologie NPC 95-01 Study. J Clin Oncol 2005;23:5910-5917.
7. Kepka L, Sprawka A, Casas F, et al. Combination of radiotherapy and chemotherapy in locally advanced NSCLC. Expert Rev Anticancer Ther 2009;9:1389-403.
8. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 2006;66:1399-1407.
9. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 2004;46:87-98. (Pubitemid 39201387)
10. Antonadou D, Throuvalas N, Petridis A, et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;57:402-408. (Pubitemid 37040936)
11. Lau D, Leigh B, Gandara D, et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/ paclitaxel consolidation for stage III non-small-cell lung cancer: A California Cancer Consortium phase II trial. J Clin Oncol 2001;19:442-447. (Pubitemid 32112857)
12. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-4198. (Pubitemid 35191021)
13. Werner-Wasik M. Treatment-related esophagitis. Semin Oncol 2005;32: S60-S66.
14. Movsas B, Scott C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 2005;23:2145-2154. (Pubitemid 46218706)
15. Danilenko DM. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol 1999;27:64-71. (Pubitemid 29075747)
16. Werner S. Keratinocyte growth factor: A unique player in epithelial repair processes. Cytokine Growth Factor Rev 1998;9:153-165. (Pubitemid 28376451)
17. Farrell CL, Bready JV, Rex KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998;58:933-939. (Pubitemid 28182461)
18. Farrell CL, Rex KL, Chen JN, et al. The effects of keratinocyte growth factor in preclinical models of mucositis. Cell Prolif 2002;35(Suppl 1): 78-85. (Pubitemid 34985150)
19. Farrell CL, Rex KL, Kaufman SA, et al. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol 1999;75:609-620. (Pubitemid 29243139)
20. Kepivance Prescribing Information Stockholm Sweden: Biovitrum AB
21. Kepivance Prescribing Information. Stockholm, Sweden: Biovitrum AB. 21. Bradley J. A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. Semin Oncol 2005;32:S111-S113.
22. Hazuka MB, Turrisi AT III, Lutz ST, et al. Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: A retrospective multivariate analysis. Int J Radiat Oncol Biol Phys 1993;27:273-284. (Pubitemid 23304453)
23. Machtay M, Swann RS, Komaki R, et al. O-265 Cisplatin dose delivery and survival in concurrent chemoradiation for stage III NSCLC: An RTOG secondary analysis. Lung Cancer 2003;41:S77.
24. Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 1980;45:2744-2753. (Pubitemid 10063330)
25. Radiation Therapy Oncology Group. High-dose or standard-dose radiation therapy and chemotherapy in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery. ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00533949?term-rtog-0617&rank-1. Accessed February 23, 2010.
26. Bradley JD, Bae K, Graham MV, et al. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. J Clin Oncol 2010;28:2475-2480.
27. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001;19:127-136. (Pubitemid 32063489)
28. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002;54:348-356. (Pubitemid 35286797)
29. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008;26: 2457-2463.
30. Pena-Greenberg E, Law E, Frankel J. Radiation-induced esophagitis: Evidence-based nursing guidelines for lungs and esophageal cancer patients. In: Oncology Nursing Society 33rd Annual Congress Oncology Nursing Forum; 2008. p. 498.
31. Schild SE, McGinnis WL, Graham D, et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65: 1106-1111.
32. Komaki R, Lee JS, Milas L, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable nonsmall- cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 2004;58:1369-1377. (Pubitemid 38438296)
33. Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008;26:2489-2496.
34. Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006;24:5194-5200. (Pubitemid 46631362)